Neurologic Complications of Cancer Therapy

Neurologic side effects of cancer therapy can inhibit treatment, can be dose-limiting and can diminish quality-of-life. Neurotoxicity related to cancer therapy is a common problem in oncology practice and in clinical neurology. Recognition of neurologic complications of anticancer therapy is necessary due to potential confusion with metastatic disease, paraneoplastic syndromes or comorbid neurologic disorders that do not require reduction or discontinuation of therapy.

Neurologic Complications of Cancer Therapy provides comprehensive coverage of the recognition and management of neurologic symptoms related to cancer therapy. The book includes sections on systemic therapy discussed by both agent and adverse event. The section on adverse events is particularly valuable to clinicians, allowing them to consult by symptom in cases where multiple agents have been administered and the source of the complication is uncertain. The systemic therapy section includes coverage of immunologic agents, biologics, and targeted therapies. The book also features sections on the complications of radiation therapy, complications of surgery and high-dose chemotherapy, and stem cell transplantation.

Neurologic Complications of Cancer Therapy Features:
A widely recognized team of editors
Systemic therapy covered by therapeutic agent and by adverse event, enabling a "problem-oriented" approach for the clinician
Coverage of newer modalities including immunologic agents, biologics, and targeted therapies
Complete sections on complications of radiation therapy, surgery, high-dose chemotherapy, and stem-call transplantion
- return to top -

Contents
Part 1: Neurologic complications of systemic therapies: According to agent: 1. Alkylating agents; 2. Antimetabolites 3. Plant Alkaloids; 4. Topoisomerase inhibitors; 5. Epothilones; 6. Amino acid degraders; 7. Corticosteroids; 8. Immunomodulatory agents; 9. Immunosuppressants; 10. Biologic Agents; 11. Targeted Therapies; 12. Hormonal therapies; 13. Supportive therapies; According to adverse event: 14. Cognitive function; 15. Central nervous system complications (except cognitive dysfunction); 16. Peripheral nervous system complications (excluding muscle and NMJ disorders); 17. Neuromuscular junction and myopathy; Part 2: Neurologic complications of radiation therapy: 18. Mechanisms of radiation damage; 19. Early CNS complications; 20. Late-delayed CNS complications; 21. Radiation-induced tumors; 22. Radiation vasculopathy; 23. Spinal cord damage; 24. Peripheral nerve damage; Part 3: Neurologic complications of surgery: 25. Surgery; Part 4: Neurologic complications of hematopoietic stem cell transplantation: 26. Hematopoietic stem cell transplantation
- return to top -

About the Authors
Patrick Wen, MD
Director, Center for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center.

David Schiff, MD

Co-Director, Neuro-Oncology Center, University of Virginia

Eudocia Quant Lee, MD

Patrick Y. Wen, MD is Director, Center for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center. David Schiff, MD is Co-Director, Neuro-Oncology Center, University of Virginia. Eudocia Quant Lee, MD Instructor in Neurology, Center for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center.